TABLE A2.
Clinical Characteristics of Patients With CCA Treated at MD Anderson Cancer Center Between 2008 and 2022 on the Basis of IDH1/2 Mutational Status
| Characteristic | IDH1 GA (n = 71) | IDH2 GA (n = 16) | IDH WT (n = 415) |
|---|---|---|---|
| Age, years, median (range) | 64 (30-83) | 60 (31-79) | 61 (21-87) |
| Sex, No. (%) | |||
| Male | 27 (38) | 6 (37.5) | 196 (47.3) |
| Female | 44 (62) | 10 (62.5) | 218 (52.6) |
| Stage, No. (%) | |||
| I or II | 14 (19.7) | 4 (25) | 69 (16.7) |
| III or IV | 41 (57.7) | 8 (50) | 345 (83.3) |
| Unknown | 16 (25.5) | 4 (25) | |
| Subtype, No. (%) | |||
| Intrahepatic | 70 (98.5) | 16 (100) | 414 (100) |
| Extrahepatic | 1 (1.5) | 0 | 1 (0.2) |
| Median number of systemic therapies, No. (%) | 2 (1-7) | 2 (0-7) | 2 (1-12) |
| Treated on clinical trial, No. (%) | 23 (32.4) | 6 (37.5) | 113 (27.2) |
| Treated with IDH1 inhibitor, No. (%) | 23 (32.4) | 0 | 0 |
| Received ChemoXRT, No. (%) | 12 (17) | 2 (12.5) | 59 (14.3) |
| Received surgery, No. (%) | 19 (26.7) | 1 (6.3) | 53 (12.8) |
| Received liver-directed therapy, No. (%) | 27 (38) | 5 (31.3) | 128 (31) |
Abbreviations: CCA, cholangiocarcinoma; GA, genomic alteration.